# Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00320528** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 269 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** atomoxetine

## Key facts

- **NCT ID:** NCT00320528
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 269 (ACTUAL)
- **Last updated:** 2010-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320528, "Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00320528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*